Eyam Health exits CDL with large-animal data and stronger pharma ties

Eyam Health says it graduated from Creative Destruction Lab’s Vancouver Biomedical stream after nine months that produced large-animal proof of concept for its Gemini platform, expanded pharma partnerships and its strongest quarter of partnership revenue. The company says the milestone moves its durable genetic medicine platform closer to IND-enabling studies and the clinic.

Why it matters: - Eyam Health says its Gemini platform has shown durable single-administration expression in large animals for nearly six months. - That could help address two core limits in genetic medicine: repeat dosing for mRNA-based approaches and redosing barriers for viral vectors. - The company is positioning the platform for long-acting biologics, redosable genetic medicines and next-generation vaccines.

What happened: - Eyam Health announced its graduation from Creative Destruction Lab’s CDL Vancouver Biomedical stream on June 11, 2026. - The company says it exited after nine months in the program. - During that period, Eyam says it validated Gemini in two large-animal species. - Eyam also says it expanded its roster of pharma partners and posted its strongest quarter of partnership revenue to date.

The details: - Gemini is a self-amplifying, LNP-free platform designed for durable, redosable in vivo expression of therapeutic proteins. - The platform is built to express antibodies, enzymes and vaccine antigens from a single administration. - Eyam says the large-animal data supports a path toward long-acting biologics, redosable genetic medicines and next-generation vaccines. - CEO Ryan Thomas said sustained single-dose expression approaching six months validates both the science and the business model. - Thomas said CDL’s mentor network pushed Eyam to think more strategically about the platform’s trajectory and pace of advancement. - Eyam says the program helped define its clinical build strategy for partnered programs, including how to advance them through IND-enabling studies and structure deals around the platform’s expanded value. - Vice President of Strategic Partnerships Dr. Pamela Housh said durable expression is changing partner conversations and creating momentum across discussions. - Housh said the company is using that interest to build structured partnerships and a disciplined path through IND-enabling studies. - Eyam says its next phase includes a pipeline spanning infectious disease, companion animal health and oncology. - IND-enabling studies are the near-term objective across the company’s lead programs.

Between the lines: - The company is moving from platform validation toward a more commercial and translational pitch. - The combination of animal data, partner growth and revenue suggests Eyam is trying to show biotech investors and pharma partners both scientific traction and business traction. - The CDL graduation also signals that Eyam sees itself as past an early experimentation stage and into execution on clinical and partnering plans.

What’s next: - Eyam says it will advance partnered programs through IND-enabling studies. - The company is also continuing development across infectious disease, companion animal health and oncology. - Eyam says it has a clear line of sight to the clinic, though no clinical timeline was disclosed.

The bottom line: - Eyam Health says its Gemini platform now has large-animal durability data and a stronger partnering base, setting up the next step from proof of concept to development-ready programs.

More information: Eyam Health